Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | PGR | P06401 | 3/20 | 0.63 |
| ▸ | IDH1 | O75874 | 4/20 | 0.61 |
| ▸ | GPR27 | Q9NS67 | 7/20 | 0.57 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762452 | 0.87 | PGR (0.74) | MEN1KMT2APGRCYP3A4 | |
| SCHEMBL29562342 | 0.86 | PGR (0.72) | MEN1KMT2APGRGPR27AVPR2 | |
| SCHEMBL12010902 | 0.84 | MEN1 (0.72) | MEN1KMT2ALMNA | |
| SCHEMBL12010876 | 0.84 | MEN1 (0.72) | MEN1KMT2AGPR27LMNA | |
| SCHEMBL2055411 | 0.83 | KMT2A (0.54) | MEN1KMT2AMAPTRAB9ANPSR1 | |
| SCHEMBL22124777 | 0.83 | MEN1 (0.65) | MEN1KMT2AMAPTPGRIDH1 | |
| SCHEMBL7326451 | 0.80 | PGR (0.64) | MEN1KMT2APGRGPR27AVPR2 | |
| SCHEMBL11897191 | 0.80 | MAPT (0.69) | MEN1KMT2AMAPTNPSR1PGR | |
| SCHEMBL12115916 | 0.79 | GPR27 (0.70) | MEN1KMT2AMAPTRAB9APGR | |
| SCHEMBL12218114 | 0.79 | MEN1 (1.00) | MEN1KMT2AMAPTRAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | MEN1 4730/4885KMT2A 2144/4885MAPT 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.